The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given ...
Dose Escalation: To evaluate the safety and tolerability of peposertib in combination with low-dose liposomal doxorubicin as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level. Dose Escalation: To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified. Dose Expansion:...
Determine the efficacy of treatment with weekly doxorubicin chemotherapy in anthracycline-naïve elderly patients with advanced or metastatic LMS of soft tissue.
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
-To determine the MTD/maximum administered dose and RP2DS of ADCE-D01. -To assess the safety and tolerability of ADCE-D01.
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
To see how safe and tolerable the study drug is when given alone and together with other anticancer drugs at different dose levels in patients; To determine the optimal dose of the study drug when given alone and together with other anticancer drugs that is effective but does not result in severe side effects; To evaluate the preliminary anti-tumor activity of the study drug when given alone and t...
This study wants to find a dose of ziftomenib that people with advanced gastrointestinal stromal tumors (CIST) can handle safely when taken with imatinib. We also want to learn how well these two drugs work together.
• To evaluate the safety and tolerability of DCC-3009 as monotherapy in participants with advanced GIST. • To determine the recommended dose(s) for expansion in Module A, and if reached, the maximum tolerated dose (MTD) of DCC-3009 as monotherapy.
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a typ...
This study wants to find a new combination of drugs that is safe and effective to treat people who have bone cancer that has come back or not responded to other treatments.
The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine".